Carboplatin-Cyclophosphamide or Paclitaxel without or with Bevacizumab as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (BOOG 2013-01).

MLA

van Rossum, Annelot G. J., et al. “Carboplatin-Cyclophosphamide or Paclitaxel without or with Bevacizumab as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (BOOG 2013-01).” Breast Care (Basel, Switzerland), vol. 16, no. 6, Dec. 2021, pp. 598–606. EBSCOhost, https://doi.org/10.1159/000512200.

APA

van Rossum, A. G. J., Mandjes, I. A. M., van Werkhoven, E., van Tinteren, H., van Leeuwen-Stok, A. E., Nederlof, P., Portielje, J. E. A., van Alphen, R. J., Platte, E., van den Broek, D., Huitema, A., Kok, M., Linn, S. C., & Oosterkamp, H. M. (2021). Carboplatin-Cyclophosphamide or Paclitaxel without or with Bevacizumab as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (BOOG 2013-01). Breast Care (Basel, Switzerland), 16(6), 598–606. https://doi.org/10.1159/000512200

Chicago

van Rossum, Annelot G J, Ingrid A M Mandjes, Erik van Werkhoven, Harm van Tinteren, A Elise van Leeuwen-Stok, Petra Nederlof, Johanna E A Portielje, et al. 2021. “Carboplatin-Cyclophosphamide or Paclitaxel without or with Bevacizumab as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (BOOG 2013-01).” Breast Care (Basel, Switzerland) 16 (6): 598–606. doi:10.1159/000512200.